{"id":8216,"date":"2020-07-06T12:00:20","date_gmt":"2020-07-06T16:00:20","guid":{"rendered":"http:\/\/localhost:10028\/uncategorized\/history-of-us-pharmaceutical-lawsuits\/"},"modified":"2022-08-18T21:16:09","modified_gmt":"2022-08-19T01:16:09","slug":"history-of-us-pharmaceutical-lawsuits","status":"publish","type":"post","link":"https:\/\/napolilaw.lemonadestand.org\/en\/article\/history-of-us-pharmaceutical-lawsuits\/","title":{"rendered":"History of US Pharmaceutical Lawsuits"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Pharmaceutical lawsuits have resulted in many million- and even billion-dollar settlements throughout US legal history. Filing a lawsuit isn\u2019t a get-rich-quick scheme; for one thing, the process is rarely quick. In some cases, filing a lawsuit may be the only way to hold manufacturers accountable for the harmful effects of their medications and to obtain the financial resources to care for conditions that have been caused by their negligence.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Many times, lawsuits are filed when manufacturers fail to warn doctors and patients about the long-term or dangerous side effects of a drug or medical device. When manufacturers withhold this information, doctors cannot communicate with their patients about the benefits and risks of the product. As a result, patients will be prescribed the product and could eventually experience serious health problems.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Here is some of the history of why pharmaceutical lawsuits occur and recent cases of pharmaceutical negligence.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Direct-to-Consumer Drug Advertising in the US<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The US is <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3278148\/#:~:text=7%2C9-,What%20Is%20Direct%2Dto%2DConsumer%20Drug%20Advertising%3F,prescription%20products%20directly%20to%20patients.&amp;text=The%20U.S.%20and%20New%20Zealand,DTCPA%20that%20includes%20product%20claims.\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">one of the few countries<\/span><\/a><span style=\"font-weight: 400;\"> that allows direct-to-consumer pharmaceutical advertising (DTCPA) for pharmaceutical drugs. Direct-to-consumer advertising for medications began in the early twentieth century, when there were only a few types of drugs on the market.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 1905, the Council on Pharmacy and Chemistry, appointed by the American Medical Association, <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2690298\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">discouraged DTCPA<\/span><\/a><span style=\"font-weight: 400;\"> by labeling drugs marketed to the general public as \u201cnon-ethical,\u201d supporting only those that were marketed directly to medical professionals. However, DTCPA was never made illegal.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In 1906, the passing of the Pure Food and Drug Act created federal standards for educating patients on the effects of drugs, disclosing ingredients and including proper labeling, and not misrepresenting the drug\u2019s effects. Then, additional regulations in 1938 and 1951 placed medications under additional federal restrictions in order to regulate their advertising, distribution, and use to protect consumers.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Although most manufacturer advertisements were initially aimed at physicians, direct-to-consumer advertisements have increased dramatically. Today, these advertisements add up to about 40 percent of the amount pharmaceutical companies spend on promotions. And although federal guidelines are designed to keep drugs safe for consumers, they aren\u2019t always enough to stop harmful drugs from getting through to the public.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Due to the increased use of mass media to advertise prescription drugs that treat diabetes, cholesterol, erectile dysfunction, depression, pain, and a host of other conditions, consumers often engage in self-diagnosis. This leads to many consumers purchasing prescription drugs that they don\u2019t need.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Fortunately, the US healthcare system has made even more important reforms over the last three decades to secure patients\u2019 rights to information about treatment options and purchasing decisions.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The combination of direct-to-consumer pharmaceutical advertising and the high volume of medications used in the US every year leaves manufacturers and pharmaceuticals susceptible to lawsuits when drugs are misrepresented or their harmful effects are not fully disclosed, perhaps more so than in any other country.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Largest Recent Pharmaceutical Lawsuits<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">In the nearly three decades from 1991 to 2017, pharmaceutical manufacturers settled 412 cases with federal and state governments, paying a total of $38.6 billion for everything from false advertising to withholding knowledge of proven side effects.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Two of the largest pharmaceutical settlements in the US involved the companies GlaxoSmithKline and Takeda Pharmaceuticals.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">GlaxoSmithKline: $3 billion<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In 2012, GlaxoSmithKline (GSK) settled <\/span><a href=\"https:\/\/www.justice.gov\/opa\/pr\/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">the biggest healthcare lawsuit in the US<\/span><\/a><span style=\"font-weight: 400;\"> with a $3 billion payment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">GSK was charged for illegally promoting some of their prescription drugs, including Avandia, Paxil, and Wellbutrin. The company had failed to report some of the safety data to the FDA and also gave false drug prices in order to underpay discounts under the Medicaid Drug Rebate Program.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Additionally, the company misbranded their antidepressant drugs (Paxil and Wellbutrin) and also rewarded healthcare providers for recommending them to their patients for off-label uses.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Moreover, the company failed to produce safety data for Avandia, which was intended to treat diabetes, which left many patients concerned about the drugs&#8217; cardiovascular safety.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Takeda Pharmaceuticals: $2.4 billion<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">In 2015, a pharmaceutical lawsuit was filed against Takeda Pharmaceuticals. The company was found guilty for concealing bladder cancer risks related to their oral diabetes drug, Actos. <\/span><a href=\"https:\/\/www.drugwatch.com\/news\/2015\/04\/29\/takeda-actos-settlement-2-billion\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">The company settled<\/span><\/a><span style=\"font-weight: 400;\"> the over 8,000 federal and state lawsuits by paying $2.4 billion.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Actos was the company\u2019s top-selling drug after it was approved in 1999 by the FDA. It became more popular after GlaxoSmithKline\u2019s diabetic drug (Avandia) was restricted due to its cardiovascular safety concerns.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">After the restriction of Avandia, Takeda advertised their top-selling drug claiming that it could lower blood sugar without increasing the risk of stroke or heart attack. However, the company was sued for misleading the public about the claimed benefits of the drug, which overlooked the harsh side effects.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Current Pharmaceutical Lawsuits<\/span><\/h2>\n<p><a href=\"\/practice-areas\/pharmaceutical-litigation\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Pharmaceutical litigation attorneys<\/span><\/a><span style=\"font-weight: 400;\"> at Napoli Shkolnik  are currently involved in several lawsuits involving the misrepresentation and resulting harmful effects of pharmaceuticals.\u00a0<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Opioid Lawsuits<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">The US opioid epidemic that has developed over the past several decades is now resulting in severe negative consequences for individuals and communities. Currently, opioid-related lawsuits are in progress against pharma companies, dispensaries, and retail pharmacies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Napoli Shkolnik\u2019s Opioid Trial Team was part of the landmark Ohio bellwether $320 million settlement in fall 2019. The firm is also leading the next round of opioid trials, which were scheduled in New York for March 2020 before being postponed due to COVID-19.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Opioids are a group of pain-relieving drugs that interact with the opioid receptors in your cells. When used as recommended by a doctor and in small doses, these medications can help control acute pain. However, their addictive nature has been severely underrepresented for years, resulting in overprescription, addiction, and devastating numbers of overdose deaths.<\/span><\/p>\n<p><a href=\"\/office-of-governmental-affairs-opioid-lawyers\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Opioid lawsuits<\/span><\/a><span style=\"font-weight: 400;\"> are all aimed at holding opioid producers and their distributors accountable for the opioid epidemic that has ravaged the United States.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Elmiron Lawsuits<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Janssen Pharmaceuticals has been accused of failing to inform consumers about the potential vision loss caused by the drug Elmiron.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to recent studies, the drug, which is used to treat interstitial cystitis and resulting bladder pain, <\/span><a href=\"\/article\/bladder-medication-can-cause-blindness\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">can cause irreversible vision damage<\/span><\/a><span style=\"font-weight: 400;\"> due to its ocular toxicity. Research presented at the American Academy of Ophthalmology in 2019 revealed that patients taking the drug showed signs of toxicity.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you have taken Elmiron and suffered from vision loss, you may be entitled to compensation. Consumers have the right to make informed decisions about their health, and the <\/span><a href=\"\/practice-areas\/pharmaceutical-litigation\/national-elmiron-eye-disease-lawyers\/\" target=\"_blank\" rel=\"noopener noreferrer\"><span style=\"font-weight: 400;\">Elmiron lawsuit<\/span><\/a><span style=\"font-weight: 400;\"> holds Janssen Pharmaceuticals responsible for denying patients that information and right.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">If you are experiencing severe health effects after taking a drug that was defectively manufactured or without being informed of its effects, you can help hold the pharmaceutical companies accountable by raising your voice.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical lawsuits have resulted in many million- and even billion-dollar settlements throughout US legal history. Filing a lawsuit isn\u2019t a get-rich-quick scheme; for one thing, the process is rarely quick&#8230;.<\/p>\n","protected":false},"author":3,"featured_media":8217,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[776],"tags":[],"class_list":["post-8216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceutical-litigation"],"acf":[],"page_builder_type":"gutenberg","gutenberg_data":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/posts\/8216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/comments?post=8216"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/posts\/8216\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/media\/8217"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/media?parent=8216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/categories?post=8216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/en\/wp-json\/wp\/v2\/tags?post=8216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}